Depression and Anxiety Disorders Drug Development Pipeline Review, 2018 – ResearchByMarkets

Depression and Anxiety Disorders Drug Development Pipeline Review, 2018

This report provides an overview of the pipeline landscape for depression and anxiety disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD) and depression, and features dormant and discontinued products.

PTSD is a mental health condition that is triggered by either experiencing or witnessing a traumatic event. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants and cognitive therapy. There are 38 products in development for this indication.

OCD is characterized by unreasonable thoughts and fears (obsessions) that lead to repetitive behaviors (compulsions). Symptoms include having repeated thoughts or images about many different things, such as fear of germs, dirt, or intruders, acts of violence, hurting loved ones, doing the same rituals over and over such as washing hands, locking and unlocking doors, counting, keeping unneeded items, or repeating the same steps again and again. Treatment includes antidepressants and psychiatric medications. There are nine products in development for this indication.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers and antipsychotics. There are 212 products in development for this indication.

Molecular targets acted on by products in development for depression and anxiety disorders include neurotransmitter receptors such as glutamate receptors and 5-hydroxytryptamine receptors. Companies operating in this pipeline space include NeuroRx, Amorsa Therapeutics and Johnson & Johnson.



– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

– Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
– Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
– Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
– Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration.

Buy this report via Credit Card/Paypal or Wire Transfer:

Companies Mentioned: 
Acadia Pharmaceuticals Inc
Ache Laboratorios Farmaceuticos SA
Actinogen Medical Ltd
Adamed Sp z oo
Addex Therapeutics Ltd
Aequus Pharmaceuticals Inc
Albany Molecular Research Inc
Alkermes Plc
Allergan Plc
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Aptinyx Inc
Avanir Pharmaceuticals Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
BioCrea GmbH
Biohaven Pharmaceutical Holding Company Ltd
Bionomics Ltd
BioXcel Therapeutics Inc
Blackthorn Therapeutics Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Calico LLC
Catalyst Pharmaceuticals Inc
Celgene Corp
Cellix Bio Pvt Ltd
Celon Pharma SA
Cerecor Inc
Chronos Therapeutics Ltd
Clera Inc
Corcept Therapeutics Inc
Delpor Inc
Eisai Co Ltd
Eli Lilly and Co
Embera NeuroTherapeutics Inc
Fabre-Kramer Pharmaceuticals Inc
FPRT Bio Inc
GlaxoSmithKline Plc
GliaCure Inc
H. Lundbeck AS
Heptares Therapeutics Ltd
Immodulon Therapeutics Ltd
Impel NeuroPharma Inc
Intas Pharmaceuticals Ltd
IntelGenx Corp
Intra-Cellular Therapies Inc
Jiangsu Nhwa Pharmaceutical Corp Ltd
Johnson & Johnson
Karuna Pharmaceuticals Inc
KemPharm Inc
Kissei Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Mapi Pharma Ltd
Mapreg SAS
MedinCell SA
Medlab Clinical Ltd
Meta-IQ ApS
Mitsubishi Tanabe Pharma Corp
Navitor Pharmaceuticals Inc
Neuralstem Inc
Neurocrine Biosciences Inc
NeuroNascent Inc
Nippon Chemiphar Co Ltd
Novartis AG
Omeros Corp
Otsuka Holdings Co Ltd
Pfizer Inc
Pherin Pharmaceuticals Inc
Pragma Therapeutics SAS
Protagenic Therapeutics Inc
Relmada Therapeutics Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Shenox Pharmaceuticals LLC
SK Biopharmaceuticals Co Ltd
Sound Pharmaceuticals Inc
SpringWorks Therapeutics LLC
Sumitomo Chemical Co Ltd
Sumitomo Dainippon Pharma Co Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Syntropharma Ltd
Taisho Pharmaceutical Holdings Co Ltd
Takeda Pharmaceutical Co Ltd
Tonix Pharmaceuticals Holding Corp
Trevena Inc
VistaGen Therapeutics Inc

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.